Featured

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

North America Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Europe Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

#Crown Bioscience #Drug discovery #PDX models #Webinar

Beyond the model: Exploring warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

Webinar date:
Supported by Crown Bioscience
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Webinar

From PK/PD and Biomarkers to decision-making: How modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

Webinars

#Business #Drug development #Drug discovery #Pharmacology #Pharmokinetics #Screening

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it?

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the… Read More

Webinar date:
Sponsored by BMG Labtech & CISBio
#Webinars